CClinicalTrials.gg
CompletedNCT02792660Updated Nov 21, 2018

Identification of Cerebrospinal Fluid With Injeq IQ-Needle During Paediatric Lumbar Puncture

An interventional study of Injeq IQ-Needle in Pediatric Lumbar Puncture, sponsored by Injeq Ltd. Completed at 2 sites in Finland. Open to participants aged Up to 18 Months. Per ClinicalTrials.gov, last updated 2018-11-21.

Sponsored by Injeq Ltd · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
Up to 18 Months
Sex
All
01

Study summary

This is clinical feasibility study on the device performance with paediatric patients. The main objective is to validate the performance of investigational device in distinguishing and identifying the cerebrospinal fluid (CSF) inside the subarachnoid space during a lumbar puncture on paediatric patients.

02

Conditions studied

  • Pediatric Lumbar Puncture

Browse trials for

03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

This study's enrollment of 40 is below the median of 52 across 3,239 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Injeq Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children whose diagnosis or treatment plan requires lumbar puncture to acquire a CSF sample.
  • Consent from the parents

Exclusion criteria

Exclusion Criteria:

  • Being a high risk patient (as determined by the investigator)
  • Any contraindication to a common lumbar puncture apply also in the investigation
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Injeq IQ-Needle

    Lumbar puncture is performed using Injeq IQ-Needle

    Device: Injeq IQ-Needle

Interventions

  • DeviceInjeq IQ-Needle

    Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.

06

What researchers measure

Primary outcomes

  1. Number of true/false positive and true/false negative detections of cerebrospinal fluid marked in case report form

    Measurement device indicates with a sound and visual feedback when needle reaches cerebrospinal fluid (CSF). Physician verifies the location by removing the needle stylet and testing whether CSF flows from the needle, similarly as in traditional process. Detection is true positive if CSF flows from the needle and false positive if not. Even if the device does not detect CSF, physician performs the CSF test when needed. Physician marks to the case report form whether the device provided detections during the lumbar puncture and were the detections true or false detections.

    Time frame: During lumbar puncture

07

Study locations

2 sites
  • Tampere University Hospital
    Tampere, FI-33521, Finland
  • Turku University Hospital
    Turku, 20521, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02792660
Lead sponsor
Injeq Ltd
Responsible party
Sponsor
First posted
Jun 7, 2016
Start date
Jul 2016
Primary completion
Jun 2018
Completion
Nov 2018
Last update
Nov 21, 2018

Study contacts

Vesa Eskola, PhD MD
principal investigator · Tampere University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion